In recent years, many studies have been undertaken to describe ARV-associated weight gain. Studies have explored the different drug classes (integrase inhibitors), the impact of specific ARVs on weight gain (DTG, BIC, TAF), as well as which patients (women) are more prone to gaining weight.
With integrase inhibitors being the preferred drug class in first-line regimens, weight gain becomes an issue the healthcare provider must consider when choosing an antiretroviral regimen. While the mechanism of weight gain is still under investigation by several studies, it is essential to realize that it is a real issue affecting the physical and mental health of people living with HIV.
Increases in weight gain have been associated with a rise in metabolic changes and comorbidities which, in the long term, will have a significant impact on the quality of life for people living with HIV.
Most studies focus on a healthcare provider's perspective of selecting the most optimal therapy, resulting in a rapid decrease in viral load below the level of detection, an increase in CD4 cells, and minimal side effects.
How do changes in body shape affect the daily life of the patient?
Could it lead to negative body image, self-worth, or peer pressure?
This 3-hour virtual program offers an educational opportunity for healthcare practitioners to learn about and discuss the impact of weight gain from the patient's perspective.
